We are live on ! Find out more
SPRO icon

Spero Therapeutics

94 hedge funds and large institutions have $273M invested in Spero Therapeutics in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 8

6% more funds holding

Funds holding: 8994 (+5)

4% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 26

7.31% less ownership

Funds ownership: 70.19%62.88% (-7.3%)

26% less capital invested

Capital invested by funds: $370M → $273M (-$97M)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

44% less call options, than puts

Call options by funds: $889K | Put options by funds: $1.58M

Holders
94
Holders Change
+5
Holders Change %
+5.62%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
15
Increased
27
Reduced
26
Closed
8
Calls
$889K
Puts
$1.58M
Net Calls
-$690K
Net Calls Change
-$151K
Name Holding Trade Value Shares
Change
Change in
Stake
Rockefeller Capital Management
101
Rockefeller Capital Management
New York
+$176 +10 New

SPRO Hedge Fund Activity: Q1 2021 in Review

94 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2021, worth a combined $273M — down 26% from $370M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new SPRO positions and 8 closed out — a net gain of 7 holders — while 27 added to existing stakes and 26 trimmed.

The largest buyer was State Street, adding an estimated $17.9M. The largest seller was Rock Springs Capital Management, cutting an estimated $4.74M.

  • 94 institutional investors held Spero Therapeutics (SPRO) as of Q1 2021, up from 89 in Q4 2020.
  • Funds reported $273M of Spero Therapeutics stock for Q1 2021, down 26% quarter-over-quarter.
  • 15 funds opened new Spero Therapeutics positions in Q1 2021 and 8 closed out, a net change of +7 holders.
  • The largest Spero Therapeutics buyer in Q1 2021 was State Street, an estimated $17.9M added.
  • The largest Spero Therapeutics seller in Q1 2021 was Rock Springs Capital Management, an estimated $4.74M sold.

Based on aggregated 13F filings for Q1 2021.